Quick Answer
Ernexa Therapeutics Inc. reported Operating Income Loss of -$9.32 million for the year ending 2025.
- Ernexa Therapeutics Inc. showed an increase of +40.5% in Operating Income Loss from 2024 to 2025.
- This data is from Ernexa Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Ernexa Therapeutics Inc.'s Operating Income Loss has declined by 2,767.4%.
- Historical annual values: Fiscal year 2025: -$9.32 million | Fiscal year 2024: -$15.67 million | Fiscal year 2023: -$21.14 million | Fiscal year 2022: -$33.22 million | Fiscal year 2021: -$113.73 million | Fiscal year 2020: -$26.49 million | Fiscal year 2019: -$1.76 million | Fiscal year 2018: $203.0 thousand | Fiscal year 2017: -$1.40 million | Fiscal year 2016: -$2.28 million | Fiscal year 2015: -$6.90 million | Fiscal year 2014: -$4.74 million | Fiscal year 2013: -$1.12 million | Fiscal year 2012: -$1.06 million | Fiscal year 2011: -$3.28 million | Fiscal year 2010: -$325.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: